许静毅 文献 冯海璇



[摘要]目的 探討特布他林联合异丙托溴铵治疗慢性阻塞性肺疾病(COPD)的临床效果。方法 选取2017年1月1日~2018年12月31日我院收治的153例COPD患者,按奇偶分组法将其分成参照组(75例)及观察组(78例),参照组行特布他林治疗,观察组行特布他林联合异丙托溴铵治疗。分析、比较两组患者的血气指标、肺功能指标水平及临床疗效。结果 经治疗后,观察组动脉血氧饱和度(SaO2)、动脉血氧分压(PaO2)水平高于参照组,二氧化碳分压(PaCO2)水平低于参照组,差异有统计学意义(P<0.05);观察组1 s用力呼吸容积(FEV1)、用力肺活量(FEV1/FVC)、呼吸量峰值(PEF)水平均高于参照组,差异有统计学意义(P<0.05);观察组临床总有效率为83.33%(65/78),高于参照组(50.67%),差异有统计学意义(P<0.05)。结论 特布他林联合异丙托溴铵治疗COPD的临床效果较佳,可改善患者血气指标及肺功能指标,对其病情的稳定起到积极作用。
[关键词]慢性阻塞性肺疾病;特布他林;异丙托溴铵;临床疗效
[中图分类号] R562.22 [文献标识码] A [文章编号] 1674-4721(2020)5(b)-0055-03
Clinical effect of Terbutaline combined with Ipratropium Bromide in the treatment of chronic obstructive pulmonary disease
XU Jing-yi WEN Xian FENG Hai-xuan
Department of Respiratory Medicine, Shenzhen Luohu District People′s Hospital, Guangdong Province, Shenzhen 518000, China
[Abstract] Objective To investigate the clinical effect of terbutaline combined with Ipratropium Bromide in the treatment of chronic obstructive pulmonary disease (COPD). Methods A total of 153 patients with COPD admitted to our hospital from January 1, 2017 to December 31, 2018 were enrolled in this study. They were divided into reference group (75 cases) and observation group (78 cases) according to the parity grouping method. The reference group was treated with Terbutaline, the observation group was treated with Terbutaline combined with Ipratropium Bromide. The blood gas index, lung function index and clinical efficacy of the two groups of patients were analyzed and compared. Results After treatment, the levels of arterial oxygon sataration (SaO2) and arterial partial pressure of oxgyon (PaO2) in the observation group were higher than those in the reference group, and the level of arterial pantial pressure of carbon dvoxide (PaCO2) was lower than that in the reference group, the differences were statistically significant (P<0.05). The forced expiratory volume in the first second (FEV1), forced vital capacity (FEV1/FVC) and peak expiratony flow (PEF) levels in the observation group were higher than those in the reference group, the differences were statistically significant (P<0.05). The total effective rate of the observation group was 83.33% (65/78), which was higher than that of the reference group (50.67%), and the difference was statistically significant (P<0.05). Conclusion The clinical effect of Terbutaline combined with Ipratropium Bromide in the treatment of COPD is better, which can improve the blood gas index and lung function index of patients, and play a positive role in the stability of the disease.
[Key words] Chronic obstructive pulmonary disease; Terbutaline; Ipratropium Bromide; Clinical efficacy
慢性阻塞性肺疾病(COPD)简称慢阻肺,属于呼吸系统疾病,于临床中较常见,该病特征为不完全可逆的气流受限,随着病情发展,该病呈进行性加重,对肺功能产生不同程度的损害,与此同时可引发全身炎症以及呼吸衰竭等不良反应,严重威胁到患者生命安全[1-2]。近年来,随着环境污染越发严重,COPD发病率随之呈升高趋势[3]。β2受体激动剂是支气管舒张剂一线常见药物,主要经舒张支气管、激活β受体,使得呼吸困难等临床症状得到缓解,但是该药物单独使用效果不太理想,需联合其他药物使用[4]。抗胆碱药对呼吸道炎性反应具有抑制作用,且可抑制活性物质的释放,进而缓解平滑肌痉挛症状,利于呼吸道疾病的康复。本研究选取153例COPD患者,对其分别进行特布他林治疗与特布他林联合异丙托溴铵治疗,并对其治疗效果展开分析,现报道如下。……